Bruce Goldsmith
Keine laufenden Positionen mehr
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Abraham Noah Oler | M | 48 |
Allos Therapeutics, Inc.
 Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 12 Jahre |
| Maxine Gowen | M | 66 | 3 Jahre | |
| Stuart M. Henderson | M | - | 3 Jahre | |
| Athena Countouriotis | M | 52 | 4 Jahre | |
| Bimal Shah | M | 48 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 12 Jahre |
| Derrell Porter | M | 53 | 3 Jahre | |
| Kathleen Borthwick | F | 48 | 3 Jahre | |
| Ira R. Harkavy | M | 75 |
University of Pennsylvania
| 32 Jahre |
| Rajesh Shrotriya | M | 79 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 12 Jahre |
| Luigi Lenaz | M | 83 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 12 Jahre |
| Thomas Brock | M | 77 |
Columbia Business School
| 26 Jahre |
| Robert J. Borghese | M | - |
University of Pennsylvania
| 32 Jahre |
| Michael E. Schick | M | 57 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 15 Jahre |
| James E. Shields | M | 72 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 12 Jahre |
| Elizabeth E. Bailey | F | 86 |
University of Pennsylvania
| 33 Jahre |
| Mark Forman | M | 60 | 3 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Stephen J. Hoffman | M | 70 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 18 Jahre |
| Stephen P. Squinto | M | 67 | 4 Jahre | |
| Kathleen Metters | M | 66 |
Lycera Corp.
 Lycera Corp. Pharmaceuticals: MajorHealth Technology Lycera Corp. develops novel oral medicines for treating autoimmune diseases and cancer. It specializes in immune metabolism, cell signaling and immune cell differentiation. The firm designed gut-directed ATPase modulator, designated LYC-30937, for the treatment of inflammatory bowel disease, and oral RORgamma agonists for diverse applications in immune-oncology. The company was founded in 2006 by Anthony William Opipari, Jr., and Gary D. Glick and is headquartered in Ann Arbor, MI. | 4 Jahre |
| David Vurgait | M | 59 |
University of Pennsylvania
| 1 Jahre |
| Paul Berns | M | 57 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 6 Jahre |
| Paul Sekhri | M | 65 |
Lycera Corp.
Lycera Corp. Pharmaceuticals: MajorHealth Technology Lycera Corp. develops novel oral medicines for treating autoimmune diseases and cancer. It specializes in immune metabolism, cell signaling and immune cell differentiation. The firm designed gut-directed ATPase modulator, designated LYC-30937, for the treatment of inflammatory bowel disease, and oral RORgamma agonists for diverse applications in immune-oncology. The company was founded in 2006 by Anthony William Opipari, Jr., and Gary D. Glick and is headquartered in Ann Arbor, MI. | 4 Jahre |
| Wissam Jabre | M | 54 |
Columbia Business School
| 6 Jahre |
| Sassan Alizadeh | M | - |
University of Pennsylvania
| 7 Jahre |
| Nishan de Silva | M | 51 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 1 Jahre |
| David Perla | M | 54 |
Colgate University
University of Pennsylvania
| 4 Jahre |
| Juan Pablo Córdoba Garcés | M | - |
University of Pennsylvania
| 5 Jahre |
| Sanjay Kumar Sanghoee | M | - |
Columbia Business School
| 2 Jahre |
| Shiv Vikram Khemka | M | 61 |
University of Pennsylvania
| 2 Jahre |
| Liam Ratcliffe | M | 60 | 3 Jahre | |
| Pablo Cagnoni | M | 60 |
Lycera Corp.
Lycera Corp. Pharmaceuticals: MajorHealth Technology Lycera Corp. develops novel oral medicines for treating autoimmune diseases and cancer. It specializes in immune metabolism, cell signaling and immune cell differentiation. The firm designed gut-directed ATPase modulator, designated LYC-30937, for the treatment of inflammatory bowel disease, and oral RORgamma agonists for diverse applications in immune-oncology. The company was founded in 2006 by Anthony William Opipari, Jr., and Gary D. Glick and is headquartered in Ann Arbor, MI.
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 2 Jahre |
| Alex Abell | M | - |
University of Pennsylvania
| 4 Jahre |
| Scott M. Gallin | M | 51 |
University of Pennsylvania
| 5 Jahre |
| Cecilia Gonzalo | F | 49 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 1 Jahre |
| Kenneth Robert Marcus | M | - |
University of Pennsylvania
| 5 Jahre |
| John W. Glomb | M | - |
University of Pennsylvania
| 12 Jahre |
| David Anderman | M | - |
University of Pennsylvania
| 4 Jahre |
| Helen Remeza | M | - |
University of Pennsylvania
| 5 Jahre |
| Darius Beni Cayetano | M | 50 |
University of Pennsylvania
| 11 Jahre |
| Gregory Z. Rush | M | - |
University of Pennsylvania
| 4 Jahre |
| Frank Mora | M | - |
Columbia Business School
University of Pennsylvania
| 7 Jahre |
| Joan Midthun Larrea | F | 58 |
University of Pennsylvania
| 4 Jahre |
| Rich Ballew | M | - |
University of Pennsylvania
| 3 Jahre |
| Patrick Heron | M | 53 | 3 Jahre | |
| David Clark | M | 56 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 8 Jahre |
| Marc H. Graboyes | M | 54 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 8 Jahre |
| Joseph Turner | M | 72 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | - |
| Timothy Patrick Lynch | M | 54 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 6 Jahre |
| Jonathan Leff | M | 55 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 7 Jahre |
| Tadataka Yamada | M | 77 | 4 Jahre | |
| David Stout | M | 69 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 3 Jahre |
| Alex Norton | M | - |
Columbia Business School
University of Pennsylvania
| 7 Jahre |
| Peter Carlin | M | 51 |
Columbia Business School
University of Pennsylvania
| 7 Jahre |
| Alex Howarth | M | 55 |
Lycera Corp.
Lycera Corp. Pharmaceuticals: MajorHealth Technology Lycera Corp. develops novel oral medicines for treating autoimmune diseases and cancer. It specializes in immune metabolism, cell signaling and immune cell differentiation. The firm designed gut-directed ATPase modulator, designated LYC-30937, for the treatment of inflammatory bowel disease, and oral RORgamma agonists for diverse applications in immune-oncology. The company was founded in 2006 by Anthony William Opipari, Jr., and Gary D. Glick and is headquartered in Ann Arbor, MI. | 4 Jahre |
| Lisa Granick | F | - |
University of Pennsylvania
| 2 Jahre |
| Priti Choksi | F | - |
University of Pennsylvania
| 4 Jahre |
| Kristy Cunningham | F | - |
University of Pennsylvania
| 4 Jahre |
| Josh Weinstein | M | 49 |
University of Pennsylvania
| 4 Jahre |
| Raphael Roettgen | M | 51 |
University of Pennsylvania
| 4 Jahre |
| Brett Aukburg | M | - |
University of Pennsylvania
| 5 Jahre |
| Rob Amir | M | - |
University of Pennsylvania
| 4 Jahre |
| Allison W. Brady | F | 53 |
University of Pennsylvania
| 4 Jahre |
| Hyon C. Park | M | 51 |
University of Pennsylvania
| 4 Jahre |
| Courtney Spaeth | F | - |
University of Pennsylvania
| 3 Jahre |
| Nicholas Ondrejka | M | - |
University of Pennsylvania
| 4 Jahre |
| Lynn Loo | M | - |
University of Pennsylvania
| 4 Jahre |
| Randall Ingber | M | 50 |
University of Pennsylvania
| 4 Jahre |
| Alejandro San | M | - |
University of Pennsylvania
| 4 Jahre |
| Arthur Butcher | M | 53 |
University of Pennsylvania
| 4 Jahre |
| Lisa Shapiro Strovink | F | - |
University of Pennsylvania
| 4 Jahre |
| Mark Yosowitz | M | 54 |
University of Pennsylvania
| 4 Jahre |
| Parag A. Majmudar | M | - |
University of Pennsylvania
| 4 Jahre |
| Jason Ruspini | M | - |
University of Pennsylvania
| 4 Jahre |
| Marc D'Olimpio | M | - |
University of Pennsylvania
| 4 Jahre |
| Timothy Shannon | M | - |
University of Pennsylvania
| 4 Jahre |
| Steve A. Foreman | M | - |
University of Pennsylvania
| 4 Jahre |
| Craig Yeshion | M | - |
University of Pennsylvania
| 4 Jahre |
| Adrian Gulich | M | - |
University of Pennsylvania
| 2 Jahre |
| Jonathan I. Grabel | M | - |
University of Pennsylvania
| 4 Jahre |
| Michael Rotgin | M | - |
University of Pennsylvania
| 4 Jahre |
| Evan S. Melrose | M | 54 |
University of Pennsylvania
| 4 Jahre |
| Greg Brogger | M | 55 |
University of Pennsylvania
| 4 Jahre |
| Katherine Lehman | F | 49 |
University of Pennsylvania
| 4 Jahre |
| Gregory D. Myers | M | 53 |
University of Pennsylvania
| 4 Jahre |
| Melanie H. Berkowitz | F | - |
University of Pennsylvania
| 4 Jahre |
| Guy Zaczepinski | M | - |
University of Pennsylvania
| 4 Jahre |
| Jonathan Orseck | M | 56 |
University of Pennsylvania
| 4 Jahre |
| Sandy Matalonis | F | - |
University of Pennsylvania
| 6 Jahre |
| Yu Ren Wang | M | 63 |
University of Pennsylvania
| 3 Jahre |
| Ron Mordechai Lior | M | - |
University of Pennsylvania
| 5 Jahre |
| David Francis Betten | M | - |
University of Pennsylvania
| 4 Jahre |
| Daniel E. Weinbach | M | - |
University of Pennsylvania
| 4 Jahre |
| Adam Borneleit | M | - |
University of Pennsylvania
| 4 Jahre |
| A. Sami Saribas | M | - |
University of Pennsylvania
| 4 Jahre |
| Mark Little | M | - |
University of Pennsylvania
| 2 Jahre |
| David Levy | M | - |
University of Pennsylvania
| 4 Jahre |
| Marc R. Lisker | M | 56 |
University of Pennsylvania
| 4 Jahre |
| Daniel J. Jansen | M | - |
University of Pennsylvania
| 2 Jahre |
| Rajeev Narang | M | - |
University of Pennsylvania
| 4 Jahre |
| Kent Bream | M | - |
University of Pennsylvania
| 4 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 100 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Bruce Goldsmith
- Persönliches Netzwerk
